The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

摘要: The proto-oncogene RAS, coding for a 21 kDa protein (p21), is mutated in 20% of lung cancer. However, the literature remains controversial on its prognostic significance survival We performed systematic review with meta-analysis to assess possible value survival. Published studies cancer assessing RAS mutation or p21 overexpression were identified by an electronic search. After methodological assessment, we estimated individual hazard ratios (HR) estimating alteration effect and combined them using meta-analytic methods. In total, 53 found eligible, 10 concerning same cohorts patients. Among 43 remaining studies, revelation method was immunohistochemistry (IHC) nine polymerase chain reaction (PCR) 34. Results terms significantly pejorative, favourable, not significant conclusive 9, 1, 31, 2, respectively. 29 evaluable but aggregated only 28 dealing non-small-cell (NSCLC) one small-cell-lung (SCLC). quality scores statistically different between without results survival, allowing us perform quantitative aggregation. HR 1.35 (95% CI: 1.16–1.56), showing worse NSCLC KRAS2 mutations and, particularly, adenocarcinomas (ADC) (HR 1.59; 95% CI 1.26–2.02) PCR 1.40; 1.18–1.65) IHC 1.08; 0.86–1.34). appears be pejorative factor globally, ADC when it studied PCR.